abrdn plc Buys 77,298 Shares of Becton, Dickinson and Company (NYSE:BDX)

abrdn plc raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 109.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 147,643 shares of the medical instruments supplier’s stock after purchasing an additional 77,298 shares during the period. abrdn plc’s holdings in Becton, Dickinson and Company were worth $36,000,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Jeppson Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 4.0% in the 3rd quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock valued at $266,000 after buying an additional 40 shares in the last quarter. CX Institutional increased its position in shares of Becton, Dickinson and Company by 3.0% during the 3rd quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock worth $385,000 after purchasing an additional 43 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its position in shares of Becton, Dickinson and Company by 3.4% during the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock worth $339,000 after purchasing an additional 43 shares in the last quarter. Value Partners Investments Inc. increased its position in shares of Becton, Dickinson and Company by 5.2% during the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 43 shares in the last quarter. Finally, Atlas Private Wealth Management increased its position in shares of Becton, Dickinson and Company by 2.9% during the 3rd quarter. Atlas Private Wealth Management now owns 1,587 shares of the medical instruments supplier’s stock worth $410,000 after purchasing an additional 45 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on BDX shares. Barclays increased their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Raymond James increased their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $280.00.

Becton, Dickinson and Company Trading Down 0.1 %

BDX opened at $233.88 on Tuesday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $67.57 billion, a PE ratio of 55.42, a PEG ratio of 1.93 and a beta of 0.43. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32. The firm has a 50-day moving average price of $239.81 and a two-hundred day moving average price of $241.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.98 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.